lenvatinib
eisai pharmaceutical
['lenva']
lenvatinib may be a 2nd line option for patients with metastatic thymic carcinoma or metastatic thymoma. a lower dose (14 mg) seems to be associated with a lower rate of aes, maintaining efficacy. #asco22 #thymictumors #oncology 
Clinical Oncologist. Clinical and Translational Research in Cancerology @gustaveroussy